These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
236 related articles for article (PubMed ID: 14521717)
1. Impact of nausea and vomiting on quality of life in cancer patients during chemotherapy. Ballatori E; Roila F Health Qual Life Outcomes; 2003 Sep; 1():46. PubMed ID: 14521717 [TBL] [Abstract][Full Text] [Related]
2. Tropisetron (Navoban) alone and in combination with dexamethasone in the prevention of chemotherapy-induced emesis: the Nordic experience. Sorbe BG Semin Oncol; 1994 Oct; 21(5 Suppl 9):20-6. PubMed ID: 9113123 [TBL] [Abstract][Full Text] [Related]
3. Prevention of chemotherapy-induced nausea and vomiting by tropisetron (Navoban) alone or in combination with other antiemetic agents. Bruntsch U; Drechsler S; Eggert J; Gosse H; Ukena D; Imhoff W; Faerber L Semin Oncol; 1994 Oct; 21(5 Suppl 9):7-11. PubMed ID: 9113120 [TBL] [Abstract][Full Text] [Related]
4. A randomized study of aprepitant, ondansetron and dexamethasone for chemotherapy-induced nausea and vomiting in Chinese breast cancer patients receiving moderately emetogenic chemotherapy. Yeo W; Mo FK; Suen JJ; Ho WM; Chan SL; Lau W; Koh J; Yeung WK; Kwan WH; Lee KK; Mok TS; Poon AN; Lam KC; Hui EK; Zee B Breast Cancer Res Treat; 2009 Feb; 113(3):529-35. PubMed ID: 18327706 [TBL] [Abstract][Full Text] [Related]
5. Comparison of the efficacy and safety of oral granisetron plus dexamethasone with intravenous ondansetron plus dexamethasone to control nausea and vomiting induced by moderate/severe emetogenic chemotherapy. Chiou TJ; Tzeng WF; Wang WS; Yen CC; Fan FS; Liu JH; Chen PM Zhonghua Yi Xue Za Zhi (Taipei); 2000 Oct; 63(10):729-36. PubMed ID: 11076429 [TBL] [Abstract][Full Text] [Related]
6. Omission of day 2 of antiemetic medications is a cost saving strategy for improving chemotherapy-induced nausea and vomiting control: results of a randomized phase III trial. Lajolo PP; de Camargo B; del Giglio A Am J Clin Oncol; 2009 Feb; 32(1):23-6. PubMed ID: 19194119 [TBL] [Abstract][Full Text] [Related]
7. The oral NK(1) antagonist, aprepitant, given with standard antiemetics provides protection against nausea and vomiting over multiple cycles of cisplatin-based chemotherapy: a combined analysis of two randomised, placebo-controlled phase III clinical trials. de Wit R; Herrstedt J; Rapoport B; Carides AD; Guoguang-Ma J; Elmer M; Schmidt C; Evans JK; Horgan KJ Eur J Cancer; 2004 Feb; 40(3):403-10. PubMed ID: 14746859 [TBL] [Abstract][Full Text] [Related]
8. Pathogenesis-based treatment of chemotherapy-induced nausea and vomiting--two new agents. Navari RM J Support Oncol; 2003; 1(2):89-103. PubMed ID: 15352652 [TBL] [Abstract][Full Text] [Related]
9. Delayed nausea and vomiting continue to reduce patients' quality of life after highly and moderately emetogenic chemotherapy despite antiemetic treatment. Bloechl-Daum B; Deuson RR; Mavros P; Hansen M; Herrstedt J J Clin Oncol; 2006 Sep; 24(27):4472-8. PubMed ID: 16983116 [TBL] [Abstract][Full Text] [Related]
10. Efficacy and tolerability of aprepitant for the prevention of chemotherapy-induced nausea and vomiting in patients with breast cancer after moderately emetogenic chemotherapy. Warr DG; Hesketh PJ; Gralla RJ; Muss HB; Herrstedt J; Eisenberg PD; Raftopoulos H; Grunberg SM; Gabriel M; Rodgers A; Bohidar N; Klinger G; Hustad CM; Horgan KJ; Skobieranda F J Clin Oncol; 2005 Apr; 23(12):2822-30. PubMed ID: 15837996 [TBL] [Abstract][Full Text] [Related]
11. [Optimal control by ondansetron of acute and prolonged emesis induced by chemotherapy without cisplatin]. Harousseau JL Bull Cancer; 1996 Jan; 83(1):71-76. PubMed ID: 8672859 [TBL] [Abstract][Full Text] [Related]
12. Acute and delayed nausea and emesis control in pediatric oncology patients. Holdsworth MT; Raisch DW; Frost J Cancer; 2006 Feb; 106(4):931-40. PubMed ID: 16404740 [TBL] [Abstract][Full Text] [Related]
13. Comparable safety and antiemetic efficacy of a brief (30-second bolus) intravenous granisetron infusion and a standard (15-minute) intravenous ondansetron infusion in breast cancer patients receiving moderately emetogenic chemotherapy. Perez EA; Lembersky B; Kaywin P; Kalman L; Yocom K; Friedman C Cancer J Sci Am; 1998; 4(1):52-8. PubMed ID: 9467047 [TBL] [Abstract][Full Text] [Related]
14. Palonosetron: a unique 5-HT3 receptor antagonist indicated for the prevention of acute and delayed chemotherapy-induced nausea and vomiting. Rubenstein EB Clin Adv Hematol Oncol; 2004 May; 2(5):284-9. PubMed ID: 16163194 [TBL] [Abstract][Full Text] [Related]
15. Addition of the neurokinin 1 receptor antagonist aprepitant to standard antiemetic therapy improves control of chemotherapy-induced nausea and vomiting. Results from a randomized, double-blind, placebo-controlled trial in Latin America. Poli-Bigelli S; Rodrigues-Pereira J; Carides AD; Julie Ma G; Eldridge K; Hipple A; Evans JK; Horgan KJ; Lawson F; Cancer; 2003 Jun; 97(12):3090-8. PubMed ID: 12784346 [TBL] [Abstract][Full Text] [Related]
16. Establishing the dose of the oral NK1 antagonist aprepitant for the prevention of chemotherapy-induced nausea and vomiting. Chawla SP; Grunberg SM; Gralla RJ; Hesketh PJ; Rittenberg C; Elmer ME; Schmidt C; Taylor A; Carides AD; Evans JK; Horgan KJ Cancer; 2003 May; 97(9):2290-300. PubMed ID: 12712486 [TBL] [Abstract][Full Text] [Related]
17. Phase 2 trial results with the novel neurokinin-1 receptor antagonist casopitant in combination with ondansetron and dexamethasone for the prevention of chemotherapy-induced nausea and vomiting in cancer patients receiving moderately emetogenic chemotherapy. Arpornwirat W; Albert I; Hansen VL; Levin J; Bandekar RR; Grunberg SM Cancer; 2009 Dec; 115(24):5807-16. PubMed ID: 19834961 [TBL] [Abstract][Full Text] [Related]
18. Antiemetic efficacy of an oral suspension of granisetron plus dexamethasone and influence of quality of life on risk for nausea and vomiting. Jordan K; Grothey A; Kegel T; Fibich C; Schöbert C Onkologie; 2005 Feb; 28(2):88-92. PubMed ID: 15662112 [TBL] [Abstract][Full Text] [Related]
19. A study evaluating the efficacy and tolerability of tropisetron in combination with dexamethasone in the prevention of delayed platinum-induced nausea and emesis. Sorbe BG; Berglind AM; Andersson H; Boman K; Högberg T; Hallgren M; Schmidt M Cancer; 1998 Sep; 83(5):1022-32. PubMed ID: 9731907 [TBL] [Abstract][Full Text] [Related]
20. The efficacy of oral ondansetron and dexamethasone for the prevention of acute chemotherapy-induced nausea and vomiting associated with moderately emetogenic chemotherapy - a retrospective audit. Ng WL; Della-Fiorentina SA Eur J Cancer Care (Engl); 2010 May; 19(3):403-7. PubMed ID: 19686353 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]